Intracellular conversion and in vivo dose response of favipiravir (T-705) in rodents infected with Ebola virus

作者：Sandra L. Bixler, Thomas Bocan, Jay Wells, Kelly S. Wetzel, Sean A. Van Tongeren, Nicole L. Garza, Ginger Donnelly, Lisa H. Cazares, Veronica Soloveva, Lisa S. Welch, Carol Epstein, Li-Fang Liang, Dennis H. Giesing, Robert Lenk, Sina Bavari, Travis K. Warren · 发表于：Antiviral Research · 年份：2017 · DOI：10.1016/j.antiviral.2017.12.020 · 被引用次数：38 · 研究领域：Viral Infections and Outbreaks Research、Disaster Response and Management、SARS-CoV-2 and COVID-19 Research

During the 2013-2016 Ebola virus (EBOV) outbreak in West Africa, our team at USAMRIID evaluated the antiviral activity of a number of compounds, including favipiravir (T-705), in vitro and in mouse and nonhuman primate (NHP) models of Ebola virus disease. In this short communication, we present our findings for favipiravir in cell culture and in mice, while an accompanying paper presents the results of NHP studies. We confirmed previous reports that favipiravir has anti-EBOV activity in mice. Additionally, we found that the active form of favipiravir is generated in mice in tissues relevant for the pathogenesis of EBOV infection. Finally, we observed that protection can be achieved in mice down to 8 mg/kg/day, which is lower than the dosing regimens previously reported. An accompanying paper reports the results of treating nonhuman primates infected with EBOV or with Marburg virus with oral or intravenous favipiravir.